AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33068445
Drug: 3-point intramuscular
RxNorm normalized name: menthol 41.3 MG/ML [ActivOn Joint & Muscle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-point intramuscular injection technique (8-12 units of incobotulinumtoxinA)
Trial: 33068445
Drug: 6-point intradermal
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-point intradermal injection technique (8-12 units of incobotulinumtoxinA)
Trial: 33068445
Drug: 3-point intramuscular
RxNorm normalized name: menthol 41.3 MG/ML [ActivOn Joint & Muscle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-point intramuscular injection technique
Trial: 33068445
Drug: 6-point intradermal
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-point intradermal injection technique
Trial: 33236464
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus add-on linagliptin
Trial: 33236464
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of metformin
Trial: 35767683
Drug: Intradialytic range-of-motion
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic range-of-motion exercises (30-minute weekly sessions)
Trial: 32870583
Drug: Intranasal chemical
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal chemical trigeminal stimulation with carbon dioxide
Trial: 35846226
Drug: Lebrikizumab 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 125 mg
Trial: 38700646
Drug: Lebrikizumab 250
RxNorm normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 250 mg
Trial: 33160359
Drug: Ramucirumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (10 mg/kg) plus docetaxel (75 mg/m2)
Trial: 33160359
Drug: Ramucirumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (10 mg/kg) plus docetaxel
Trial: 33386826
Drug: Conventional physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physiotherapy (twice a day)
Trial: 34181580
Drug: Rg1 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rg1 (5 mg) supplementation 1 hour before squat exercise
Trial: 34181580
Drug: Rg1 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rg1 (5 mg) supplementation
Trial: 35550371
Drug: Standard opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard opioid prescription (ten 5-mg oxycodone tablets provided preoperatively)
Trial: 35550371
Drug: Restricted opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted opioid prescription (provided only during patient request postoperatively)
Trial: 32652462
Drug: Weekly SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly SMS reminder
Trial: 35382842
Drug: TAK228 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK228 plus weekly paclitaxel
Trial: 35382842
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel alone (standard treatment)
Trial: 32560503
Drug: Ketogenic Diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic Diet Therapy (KDT) including classic ketogenic diet (cKD), modified Atkins diet (MAD), medium chain triglyceride ketogenic diet (MCTKD), low glycemic index treatment (LGIT)
Trial: 32518064
Drug: SU (glimepiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU (glimepiride 1 mg) + GIP (1.5 pmol/kg/min)
Trial: 32518064
Drug: SU (glimepiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU (glimepiride 1 mg) + GLP-1 (0.5 pmol/kg/min)
Trial: 32518064
Drug: SU (glimepiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU (glimepiride 1 mg) + placebo
Trial: 35955129
Drug: Eccentric hamstring
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric hamstring training (6 weeks, twice weekly) in post-PHV group
Trial: 35955129
Drug: Eccentric hamstring
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric hamstring training (6 weeks, twice weekly) in pre-PHV group
Trial: 33049804
Drug: SPN-812 (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 (1,800 mg)
Trial: 35460601
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg once daily)
Trial: 34000112
Drug: Pharmacist Comprehensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist Comprehensive Medication Management Services (PCS)
Trial: 34000112
Drug: Pharmacist Comprehensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist Comprehensive Medication Management Services (PCS) and Modified or No CMM Services (NCS)
Trial: 32925435
Drug: IVRA with
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVRA with 300 mg lidocaine
Trial: 32925435
Drug: Axillary block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axillary block with 280 mg mepivacaine
Trial: 33675672
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy along with a Stroke rehabilitation program
Trial: 33675672
Drug: Stroke rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke rehabilitation program without mirror therapy
Trial: 35286136
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus standard chemotherapy
Trial: 35696601
Drug: Local Vibration
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local Vibration Therapy (VT) for 10 minutes at 45 Hz, starting 1 hour post-exercise, applied twice daily for 48 hours
Trial: 35696601
Drug: Local Vibration
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local Vibration Therapy (VT)
Trial: 33510503
Drug: Substandard medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Substandard medicines found in health facilities
Trial: 33510503
Drug: Labeling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labeling and storage conditions of medicines
Trial: 34621011
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg/day plus androgen deprivation therapy (ADT)
Trial: 34621011
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg/day plus ADT
Trial: 33556352
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) sessions
Trial: 33556352
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (yoga, PT, education)
Trial: 34386129
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy defibrillator (CRT-D)
Trial: 33538520
Drug: Clinicopathological model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinicopathological model (4 risk factors: obstruction or perforation, lymphovascular invasion, tumor budding, no chemotherapy)
Trial: 32139135
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg kg‐1
Trial: 32139135
Drug: Neostigmine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.07 mg kg‐1 (maximum 5 mg)
Trial: 33593781
Drug: Continuous landiolol
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous landiolol infusion to reduce heart rate between 80 and 94 bpm
Trial: 32564920
Drug: Intravitreal sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal sirolimus 44 μg
Trial: 32564920
Drug: Intravitreal sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal sirolimus 440 μg
Trial: 32564920
Drug: Intravitreal sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal sirolimus 880 μg
Trial: 33305993
Drug: Oral oncolytic
RxNorm normalized name: Telomerase Specific Replication-competent Oncolytic Adenovirus
DrugBank: Suratadenoturev (DB18672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oncolytic agents (OAs)
Trial: 34487441
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin plus GLP-1 RA
Trial: 34487441
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin plus SGLT2 inhibitor
Trial: 34487441
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin intensification
Trial: 35568679
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in COU-AA-301-AAP
Trial: 35568679
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in COU-AA-302-AAP
Trial: 35568679
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in COU-AA-302-P
Trial: 35568679
Drug: Metformin pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin pooled analysis
Trial: 35951432
Drug: Xylitol chewing
RxNorm normalized name: xylitol Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol chewing gum (one piece for 15 minutes, 3 times daily)
Trial: 33443117
Drug: Gaboxadol 15
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol 15 mg evening dose (qd)
Trial: 33443117
Drug: Gaboxadol 10
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol 10 mg morning dose and 15 mg evening dose (bid)
Trial: 33443117
Drug: Placebo morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo morning dose and evening dose
Trial: 32870155
Drug: Both propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both propofol MCT and LCT preparations
Trial: 39106541
Drug: Nabiximols oromucosal
RxNorm normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols oromucosal spray
Trial: 33430665
Drug: Amlodipine (Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (Calcium Channel Blocker)
Trial: 37295665
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg daily for 12 weeks
Trial: 33597580
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg doses administered via chewing gum, four doses during night-time)
Trial: 33822798
Drug: Moringa oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa oleifera capsule
Trial: 35570039
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group, n = 144)
Trial: 33761901
Drug: US-guided bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided bilateral posterior TAPB with RSB (40 mL 0.33% ropivacaine + 20 mL 0.33% ropivacaine)
Trial: 32604406
Drug: Pimodivir 600
RxNorm normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimodivir 600 mg plus oseltamivir 75 mg twice daily for 7 days
Trial: 32604406
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus oseltamivir 75 mg twice daily for 7 days
Trial: 32678716
Drug: Neratinib (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (240 mg once daily) plus capecitabine (750 mg/m2 twice daily for 14 days of a 21-day cycle)
Trial: 32678716
Drug: Lapatinib (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,250 mg once daily) plus capecitabine (1,000 mg/m2 twice daily for 14 days of a 21-day cycle)
Trial: 33272281
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin–piperaquine (DP)
Trial: 34275096
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (20 mg daily for 5 days, followed by 10 mg daily for 5 days)
Trial: 33818302
Drug: CBT‐based Complicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT‐based Complicated Grief Treatment (CGT)
Trial: 36332541
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam (IM)
Trial: 36332541
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (IN)
Trial: 32560516
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day CLA
Trial: 35380374
Drug: ON-SXB 6
RxNorm normalized name: 2-Mercapto-6-propylpyrimid-4-one
DrugBank: Propylthiouracil (DB00550)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ON-SXB 6 g
Trial: 36252412
Drug: Twice-nightly SXB
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-nightly SXB (two 3-g doses)
Trial: 36252412
Drug: ON-SXB and
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ON-SXB and Twice-nightly SXB
Trial: 32147436
Drug: Cx32 small
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cx32 small interfering RNA and p53 inhibitor (pifithrin-α, tenovin-1)
Trial: 36451052
Drug: HDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDS with OI platform (normal vs. deep randomized oral inhalation)
Trial: 34455213
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 international units)
Trial: 33098470
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg/30 mg once daily) plus a P2Y12 inhibitor for 12 months
Trial: 33098470
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) plus a P2Y12 inhibitor and aspirin (100 mg OD, for 1–12 months)
Trial: 34386935
Drug: Oral pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pioglitazone 30 mg/day (Arm A)
Trial: 34799219
Drug: Ursolic acid
RxNorm normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursolic acid (UA) 400 mg/day
Trial: 34799219
Drug: Placebo 400
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 400 mg/day
Trial: 35811545
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (66 mg elemental iron daily as ferrous fumarate)
Trial: 33337677
Drug: Matrix Rhythm
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix Rhythm Therapy (MRT) in addition to a combined physiotherapy program (hot pack, transcutaneous electrical nerve stimulation, therapeutic ultrasound, home exercise and patient education program)
Trial: 34033974
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg/d) + Gefitinib (250 mg/d)
Trial: 34033974
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Gefitinib (250 mg/d)
Trial: 34048943
Drug: Nurse care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse care management focused on analgesic treatment and optimization (MED)
Trial: 33210299
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral thiamine (600-1800 mg/d) for 4 weeks
Trial: 33210299
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo for 4 weeks
Trial: 35485626
Drug: Routine training
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine training (physician's visits, medication prescriptions, recommendations from healthcare providers)
Trial: 36384935
Drug: Preoperative bathing
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative bathing using plain soap among participants not given preoperative antibiotics
Trial: 34609495
Drug: Deutetrabenazine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (maximum total daily dose of 48 mg/d)
Trial: 32899030
Drug: Thread embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thread embedding acupuncture (TEA), 6 treatments over 6 weeks (1 time/week) on 14 defined knee areas.
Trial: 32899030
Drug: Acupuncture treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment, 12 treatments over 6 weeks (2 times/week) on 9 defined acupuncture points.
Trial: 36262763
Drug: Dialectical Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavioral Therapy (DBT)
Trial: 35472333
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl 100 mcg
Trial: 33932433
Drug: Single flagellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single flagellar motor driving cell-body rotation; specific dosage and duration not mentioned.
Trial: 33932433
Drug: Flagellar bundles
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flagellar bundles on glass surfaces; specific dosage and duration not mentioned.
Trial: 35346849
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of intravenous tranexamic acid
Trial: 35086119
Drug: Binocular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binocular treatment with Dig Rush game (1 h/d, 5 d/wk for 8 weeks)
Trial: 34224363
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance therapy after first-line chemotherapy (FL-M)
Trial: 34224363
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance therapy after platinum-sensitive recurrence (PSR-M)
Trial: 34224363
Drug: Olaparib active
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib active treatment (AT)
Trial: 36049498
Drug: More intensive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More intensive statin regimens (40-80 mg atorvastatin or 20-40 mg rosuvastatin once per day)
Trial: 32377159
Drug: Probiotic oral
RxNorm normalized name: Rezyst Probiotic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic oral suspension group (POSG)
Trial: 32377159
Drug: Probiotic oral
RxNorm normalized name: Rezyst Probiotic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic oral suspension group (POSG) in IL-1β carriers
Trial: 34274514
Drug: Obeticholic Acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic Acid 25 mg
Trial: 34274514
Drug: Obeticholic Acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic Acid 10 mg
Trial: 36096534
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg)
Trial: 38183121
Drug: Treatment adherence
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment adherence
Trial: 34542952
Drug: Robuvit® (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robuvit® (300 mg)
Trial: 33279940
Drug: Chemotherapy consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy consolidation
Trial: 33645243
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus endocrine therapy
Trial: 34911068
Drug: IV analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV analgesics and intrapapillary local anesthetic infiltrations
Trial: 34911068
Drug: IV analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV analgesics
Trial: 35085151
Drug: Online one-day
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online one-day workshop based on cognitive behavioral therapy